Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C;Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chronique

Revue Medicale Suisse

Volumn 11, Issue 484, 2015, Pages 1610-1616

  Girardin, François ^a,b,e   Goossens, Nicolas ^c,f   Vernaz, Nathalie ^a   Negro, Francesco ^c,d  

^a Direction Médicale et Qualité ^*  (Switzerland)

^b HUG   (Switzerland)

^c Service de Gastroentérologie et Hépatologie   (Switzerland)

^d Pathologie Clinique   (Switzerland)

^e HUG   (Switzerland)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC HEPATITIS C; DRUG INDUSTRY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; REIMBURSEMENT; ECONOMICS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; REIMBURSEMENT MECHANISMS;

EID: 84940864745     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV sero-prevalence. Hepatology 2013;57:1333-42.
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastro-enterol Hepatol 2013;10:553-62.
3. Breban R, Doss W, Esmat G, et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013; 20:294-6.
4. Marinho RT, Vitor S, Velosa J. Benefits of curing he-pa titis C infection. J Gastrointestin Liver Dis 2014;23:85-90.
5. Mullhaupt B, Bruggmann P, Bihl F, et al. Modeling the health and economic burden of hepatitis C virus in Switzerland. PLoS One 2015;10:e0125214.
6. Bruggmann P, Richard JL, Swiss Hepatitis CCSG. Birth year distribution in reported hepatitis C cases in Switzerland. Eur J Public Health 2015;25:141-3.
7. Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: A changing epidemic. Swiss Med Wkly 2015; 145:w14093.
8. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012;15:887-96.
9. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;46(Suppl. 5):S165-73.
10. Ramos-Casals M, Trejo O, Garcia-Carrasco M, et al. Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9.
11. Terrier B, Saadoun D, Sene D, et al. Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: A case-control study from a single-centre cohort of 163 patients. Gut 2010;59:1709-15.
12. Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol 2011;5:503-16.
13. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59:1293-302.
14. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(Suppl. 1):34-59.
15. Trinchet JC, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015; epub ahead of print.
16. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
17. Barreiro P. Unveiling extrahepatic consequences of chronic hepatitis C-the REVEAL-HCV study. AIDS Rev 2012;14:290-1.
18. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011;364:2405-16.
19. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New Engl J Med 2013;368:1878-87.
20. Neumann PJ, Cohen JT, Weinstein MC. Updating cost effectiveness-the curious resilience of the $ 50'000 per-QALY threshold. N Engl J Med 2014;371:796-7.
21. Nimdet K, Chaiyakunapruk N, Vichansavakul K, Ngorsuraches S. A systematic review of studies elici ting willingness-to-pay per quality-adjusted life year: Does it justify CE threshold? PLoS One 2015;10:e0122760.
22. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007;43:2487-94.
23. Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984.
24. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepato-logy 2014;59:1692-705.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
27. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
28. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
29. Acosta A, Ciapponi A, Aaserud M, et al. Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2014;10:CD005979.
30. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med 2015;124:39-47.
31. McHutchison JG, Gordon SC, Schiff ER, et al. Inter feron alfa-2b alone or in combination with ribavi-rin as initial treatment for chronic hepatitis C. Hepatitis Inter ventional Therapy Group. New Eng J Med 1998;339: 1485-92.
32. Hadziyannis SJ, Sette H, Morgan TR, et al. Peg-interferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-55.
33. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Eng J Med 2011;364:1195-206.
34. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Eng J Med 2014;370:1973-82.
35. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New Eng J Med 2014;370:1983-92.
36. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Eng J Med 2014;370:1594-603.
37. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Eng J Med 2014;370:1889-98.